FDA has approved Foundayo (orforglipron), Eli Lilly's once-daily oral GLP-1 receptor agonist for obesity.

The approval marks a significant milestone in the weight management market as the first small molecule pill of its kind to reach approval and holds the potential to be the most accessible GLP-1 option for the millions of Americans who have not yet started treatment.

What is Foundayo?

Foundayo is a once-daily, non-peptide oral GLP-1 receptor agonist approved for adults with obesity or overweight with weight-related medical conditions.¹ Unlike existing injectable GLP-1 therapies and Novo Nordisk's oral semaglutide, which must be taken on an empty stomach with limited water, Foundayo can be taken at any time of day without food or water restrictions, removing a practical barrier that has complicated adherence to other oral options.¹

The drug was originally discovered by Chugai Pharmaceutical and licensed by Lilly in 2018, and was named one of the defining GLP-1 drugs of the decade in Clarivate’s new Drugs to Watch 2026 report.³

What did the clinical trials show?

The approval is based on the Attain Phase III program, which enrolled more than 4,500 people across two global trials.² In the Attain-1 trial, participants taking the highest dose who completed treatment lost an average of 27.3 pounds, a 12.4% reduction in body weight, compared to 2.2 pounds with placebo.²

Across all participants regardless of trial completion, average weight loss was 25 pounds. The drug also reduced markers of cardiovascular risk including waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure across all doses.

How will Foundayo be priced and distributed?

According to Lilly, it is positioning Foundayo as a broadly accessible option, allowing eligible patients with commercial insurance can pay as little as $25 per month with a savings card, while self-pay patients can access the lowest dose starting at $149 per month.¹

Eligible Medicare Part D enrollees may pay as little as $50 per month beginning July 1, 2026. Foundayo is expected to be available immediately through LillyDirect, with shipping beginning April 6, followed by broad availability through retail pharmacies and telehealth providers.¹

Lilly has submitted orforglipron for approval in more than 40 countries and plans to launch in each market shortly after regulatory clearance.

Why does this approval matter?

David Ricks, chair and CEO of Lilly, notes that fewer than one in ten people who could benefit from a GLP-1 therapy are currently taking one, and are held back by access barriers, stigma, and the complexity of existing treatment options.

“We believe Foundayo can help level the playing field for those living with obesity or who are overweight and living with weight-related complications," said Ricks. "As a convenient, once-daily oral pill that delivers meaningful weight loss, this is obesity care designed for the real world."

Similarly, in a conversation with Pharmaceutical Executive, Madeline Verbeke, Senior Clinical Advisor, MMIT, noted the impact oral GLP-1 products could have on patient access, saying, “I think having the oral options, we could attract a lot of new patients to this space. We have patients who have that fear or aversion to needles, and this kind of opens up the door for them, and then, even in patients without the needle phobia, the convenience of an oral option will be appealing.”

Lilly is also studying orforglipron across a broad range of additional indications including type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease, and stress urinary incontinence, signaling ambitions well beyond obesity.¹

Foundayo’s approval also makes history as the first new molecular entity (NME) approved under the National Priority Voucher Program.⁴ Issued 50 days after filing and 294 days before the application’s PDUFA date of January 20, 2027, this approval also represents a historic milestone as the fastest approval of an NME since 2002.⁴

Sources

1. FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions Eli Lilly and Company April 1, 2026 https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill
2. Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase III trial Eli Lilly and Company December 18, 2025 https://www.prnewswire.com/news-releases/lillys-orforglipron-helped-people-maintain-weight-loss-after-switching-from-injectable-incretins-to-oral-glp-1-therapy-in-first-of-its-kind-phase-3-trial-302645471.html
3. Clarivate. Drugs to Watch 2026. Online. 2026. Accessed April 1, 2026. https://clarivate.com/drugs-to-watch/
4. FDA Approves First New Molecular Entity Under National Priority Voucher Program U.S. Food and Drug Association April 1, 2026 https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program